Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIDE regimen in newly diagnosed stage III/IV or relapsed/refractory aggressive NK/T-cell lymphoma
ChiCTR-TNC-10000782Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, asparaginase escherichia coli, ifosfamide, dexamethasone and etoposide in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) and aggressive NK-cell leukemia (ANKL), sponsored by West China Hospital of Sichuan University. Primary endpoint: 2-year disease-free survival. Started Jan 2011; status: completed.
02
Drugs
gemcitabineasparaginase escherichia coliifosfamidedexamethasoneetoposide
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)aggressive NK-cell leukemia (ANKL)
Beyond the preview
Go deeper on ChiCTR-TNC-10000782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10000782.